Daily Stock List
U.S. Precious Metals, Inc. (USPR)
Streetwise Reports, Stocks That Move, and FN Media reported earlier on U.S. Precious Metals, Inc. (USPR), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
U.S. Precious Metals, Inc. engages in the acquisition, exploration, and development of mineral properties. An OTCQB-listed exploration stage company, its mission is to discover, acquire, define, and develop gold deposits and other valuable metals. The Company’s development projects are primarily in Mexico, but additionally throughout the Americas. It is focusing on gold, silver and copper mainly situated in the State of Michoacán, Mexico. U.S. Precious Metals has its corporate headquarters in Marlboro, New Jersey.
U.S. Precious Metals owns exploration and exploitation concessions to approximately 37,000 contiguous acres of mineral rights. The 17,000-hectare Solidaridad mining leases are held by U.S. Precious Metals of Mexico, a wholly owned subsidiary of the Company.
The Solidaridad properties consist of eight concessions granted by the Mexican government for a 50-year period. All information available to the Company has been attained from boreholes drilled by it and by the previous two companies that explored the property and analyzed under chain of custody by an independent laboratory.
On May 22, 2013, U.S. Precious Metals entered into an agreement with Mesa Acquisitions Group, LLC, in association with Alba Petroleos, to further explore and develop U.S. Precious Metals’ Mexican concessions. Mesa Acquisitions/Alba Petroleos committed to spend up to approximately $50 million to explore and develop pre-determined portions of two of U.S. Precious Metals’ Mexican concessions known as Solidaridad 1 & Solidaridad 2.
Furthermore, it will build the necessary plant and/or bring in the needed equipment to process the head ore. In return, it will receive 10 million shares of U.S. Precious Metals common stock and receive a 30 percent interest of the project. U.S. Precious Metals will retain 70 percent of the project.
U.S. Precious Metals acquired Resource Technology Corp. Therefore, it has incorporated the newest technological advancements in ore refining through embracing Thermal processing. This is set to transform the way ore undergoes processing in the future.
Recently, U.S. Precious Metals announced that on May 10, 2014, Mesa Acquisition Group, its Joint Venture partner, would commence the ground work phase of identifying mineralization on the approximately 2,000 acres of its 37,000 acre concession. This phase is a follow up to the satellite imaging conducted in September 2013. It includes applying the "Forming Short-Pulsed Electromagnetic Fields" (FSPEF) and "Vertical Electric-Resonance Sounding" (VERS) on the 2,000 acres identified by the previous imaging.
U.S. Precious Metals, Inc. (USPR), closed Thursday's trading session at $0.134, up 0.07%, on 108,590 volume with 20 trades. The average volume for the last 60 days is 165,351 and the stock's 52-week low/high is $0.104/$0.27.
Sanomedics International Holdings, Inc. (SIMH)
Pumps and Dumps, DSR News, Center Stage Stocks, Trading Wall St, and Pennystocktweeters.com reported recently on Sanomedics International Holdings, Inc. (SIMH), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Miami, Florida-based, Sanomedics International Holdings, Inc. is a medical technology holding Company whose shares trade on the OTC Markets’ OTCQB. The Company focuses on game-changing products, services, and ideas - that physicians, entrepreneurs, and medical companies can work together to drive innovative technologies via concept, development, and eventually commercialization. Sanomedics manufactures and distributes unique professional medical and home health diagnostic devices and products.
The Company’s goal is to act as a bridge between the high-technology medical world and the home healthcare environment. Sanomedics announced in September 2013 that it completed the acquisition of Prime Time Medical, Inc., of Largo, Florida. Prime Time Medical is a leading Durable Medical Equipment (DME) provider of home medical equipment.
The design of all Sanomedics professional and home healthcare diagnostic products are to be user-friendly. This is while providing a high degree of health benefits and accurate results. Sanomedics’ plan is to grow its existing business organically and by way of strategic acquisitions specifically relating to sleep disorder diagnosis treatments. The Company looks to acquire sleep therapy service operating businesses that can undergo integration into its operations. Moreover, the Company will look for acquisition and development opportunities related to other aspects of the sleep disorder marketplace.
Sanomedics’ strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Its goal is to provide Sleep Apnea patients with a reliable and integrated "end-to-end" service platform. Sanomedics subsidiaries include Anovent and Thermomedics. Anovent has created an innovative vision for the future of Ear, Nose and Throat (ENT) physicians and their sleep disorder patients. Thermomedics designs, develops, and markets medical diagnostic equipment for professional healthcare providers.
Earlier this month, Sanomedics announced that its new subsidiary, SanoER LLC, signed a Letter of Intent (LOI) to acquire a freestanding 5,000 sq. ft., state of the art emergency room. It will accommodate six physicians plus staff, in Harlingen, Texas. Dr. Richard Joe Ybarra, MD, will oversee the management and expansion of these facilities. This facility will be the first in Sanomedics’ overall strategy to become a major operator of Free Standing Emergency Rooms in this market. SanoER specializes in the development, management and acquisition of Freestanding Emergency Rooms (FSER).
Sanomedics International Holdings, Inc. (SIMH), closed Thursday's trading session at $0.42, down 1.18%, on 13,650 volume with 7 trades. The average volume for the last 60 days is 29,466 and the stock's 52-week low/high is $0.355/$24.00.
BioCorRx, Inc. (BICX)
SmallCapVoice, PennyStocks24, OTPicks, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, Shiznit Stocks, and MassiveStockProfits reported earlier on BioCorRx, Inc. (BICX), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Santa Ana, California, BioCorRx, Inc. is a leader in addiction treatment and rehabilitation programs. The Company has developed a highly effective program called the Start Fresh Program™ consisting of two components used by various addiction clinics in the United States. BioCorRx’ vision is to work to make the Start Fresh Program™ the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. BioCorRx’s shares trade on the OTC Markets’ OTCQB.
Clinic reports show that the Start Fresh Program™ has an 85 percent success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician, which delivers therapeutic levels of the drug Naltrexone into the body. Naltrexone is an opioid antagonist that significantly reduces physical cravings for alcohol and opioids.
The second component of the program developed by BioCorRx is a one-on-one coaching program. This program is specifically tailored for the treatment of alcoholism and other substance abuse addictions.
BioCorRx announced in March the expansion of its Start Fresh Program™. The Company is opening up the program to treat opioid addiction, because of an escalating problem to society, as well as patient demand.
In May, BioCorRx announced it entered into a Letter of Intent (LOI) to sell the exclusive license and distribution rights of its Start Fresh Program to DanBar Partners for the state of Nevada. Under the terms of the pending agreement, DanBar Partners will agree to pay BioCorRx a one-time upfront license fee plus an ongoing upfront fee per program order in the state of Nevada.
Moreover, in May, BioCorRx announced the completion of the exclusive license and distribution agreement of its Start Fresh Program to Sobriety and Addictions Solutions, LLC (formerly Fresh Start NoCal, LLC). Under the terms of the agreement, Sobriety and Addictions Solutions will pay BioCorRx a one-time upfront licensing fee plus an ongoing fee per program order in the states of Maryland, Virginia, West Virginia, North Carolina and the District of Columbia. Sobriety and Addictions Solutions presently has the licensing rights to Northern California in a transaction that completed last year.
BioCorRx, Inc. (BICX), closed Thursday's trading session at $0.096, up 4.35%, on 44,625 volume with 7 trades. The average volume for the last 60 days is 124,529 and the stock's 52-week low/high is $0.025/$0.31.
US Tungsten Corp. (USTU)
PennyStocks24, Pumps and Dumps, PennyStocks Forever, Club Penny Stocks Network, Stock Hideout, Stock Roach, and Insiders Lab reported earlier on US Tungsten Corp. (USTU), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
An exploration stage company, US Tungsten Corp. is seeking to become the first domestic producer of tungsten in nearly 50 years. The Company has staked substantial area in Southwest Montana. This includes the historic Brown's Lake Production area and the flagship Calvert Project. The Company previously went by the name Stealth Resources, Inc. It changed its name to US Tungsten Corp. in August of 2012. US Tungsten’s shares trade on the OTC Markets’ OTCQB. Founded in 2007, the Company has its headquarters in Henderson, Nevada.
Tungsten has classification as a "Strategic Metal" in the United States. It is essential to national defence and the domestic aerospace and energy industries. In addition, tungsten is subject to potential supply restrictions. The United States needs tungsten for everything from tools to missiles to light bulbs. The nation requires approximately 20,000 metric tonnes of tungsten each year to meet vital industrial demand. Approximately 90 percent of the U.S.’s tungsten is imported. The remainder comes from scrap recycling.
US Tungsten engages in the acquisition and exploration of mineral properties with a view to exploiting any mineral deposits it discovers. The Company has an option to acquire three unpatented mineral claims and own a 100 percent interest in 195 mineral claims situated in Calvert, Montana (collectively: the Calvert Property). Its plan of operation is to conduct exploration work on the Calvert Property with the intention of determining whether it possesses economic quantities of tungsten.
US Tungsten’s current plan of operation is to complete the geologist recommended work on the Calvert Property, consisting of verifying the historical in-situ reserves and a regional exploration program to evaluate the potential for discovering additional reserves along strike. The Company estimates that the cost of this program will be approximately $100,000.
In late November 2013, US Tungsten provided an update to its shareholders. The Company was affected by the early winter storms at the Calvert Project site. However, approximately 50 percent of the geophysical survey was completed. Its technical advisors indicated that the magnetic 'signatures' the Company would expect to find were present.
US Tungsten, based upon these findings, will be applying to the U.S. Forest Service for permission to conduct confirmation drilling at the Calvert Project site. Upon receiving permission, it hopes to commence the two to three week program at the earliest opportunity this year, based upon the weather and permitting constraints in Southwest Montana.
US Tungsten Corp. (USTU), closed Thursday's trading session at $0.057, even for the day, on 23,183 volume with 9 trades. The average volume for the last 60 days is 72,285 and the stock's 52-week low/high is $0.0511/$0.38.
LYFE Communications, Inc. (LYFE)
SmallCapVoice reported earlier on LYFE Communications, Inc. (LYFE), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
LYFE Communications, Inc. is developing a technology base for next generation entertainment and communications. The Company’s wholly owned subsidiary is Connected Lyfe, Inc., its main customer acquisition, operations, and services division. Through this subsidiary, LYFE Communications is integrating television, ultra-high-speed Internet, and enhanced voice services for delivery through Internet using IP (Internet Protocol). LYFE Communications is based in Salt Lake City, Utah. The Company lists on the OTCQB.
LYFE develops, deploys, and operates a proprietary converged network services platform delivering next generation media and communications services to subscribers through a single broadband connection, across diverse connected home and portable devices. The Company’s patent-pending innovations transform traditional digital television into a highly flexible IP (Internet Protocol)-based network service. This offers subscribers strong new features including the delivery of standard definition TV, HDTV and Video-on-Demand across almost any IP network to any connected device by way of a single, integrated service.
LYFE provides high-speed data and voice services to consumers in six cities. It will deploy next generation television services, with voice and data access, into each of these markets. At present, LYFE is under contract to provide its Data and Telephony services to 28 MDU properties spanning the six cities in two states. These properties present a total market opportunity of over 12,000 units.
These contracts are bulk or subscription. A bulk contract allows LYFE to provide services to every tenant at the complex. Currently, LYFE has three bulk contracts with a total customer base of 600. The remaining 25 contracts are subscription; it has either an exclusive or non-exclusive marketing contract and/or Right of Entry (ROE) at the property.
Beyond these markets, LYFE Communications will deploy its innovative platform through acquisitions, partnerships, as well as technology licensing to major existing service providers. The Company’s technology innovations take traditional digital television delivery and convert it to an adaptive IP-based service. The result is considerably lower cost of operation, new interactive capabilities, and delivery to any device, in any location, at any time. LYFE is currently negotiating with some of the nation’s largest real estate investment trusts (REIT's) and property management groups to provide services to the properties they own and manage.
LYFE Communications, Inc. (LYFE), closed Thursday's trading session at $0.0474, up 6.76%, on 88,800 volume with 9 trades. The average volume for the last 60 days is 95,860 and the stock's 52-week low/high is $0.0061/$0.12.
NutraNomics, Inc. (NNRX)
The QualityStocks Daily Newsletter would like to spotlight NutraNomics, Inc. (NNRX). Today, NutraNomics, Inc. closed trading at $0.064, up 0.79%, on 5,390 volume with 2 trades. The stock’s average daily volume over the past 60 days is 185,832, and its 52-week low/high is $0.06/$1.48.
NutraNomics, Inc. announced today that they have partnered with full-service investment banking boutique dedicated to serving the specialized needs of small-cap public companies, Stonegate. Regarded as an investment guru, Stonegate provides research, sales and trading, corporate finance, strategic advisory and investor relations services to its select group of clients.
NutraNomics, Inc. (NNRX) is focused on the research and development of nutritional dietary supplements, skin and body care products and transdermal patches. In addition to creating formulas for hundreds of companies, the company has produced and branded its own product lines which are sold through retail and wholesale channels. Additionally the company private labels and does custom manufacturing for several supplement companies in national and international markets.
Nearly all vitamins currently on the market are isolated and/or synthetic. The human body doesn’t recognize these types of vitamins and as a result cannot absorb them because they are either missing critical nutritional components or are not food based. NutraNomics has rapidly grown its business over the past 18 years by offering superior food and plant-based products blended from the highest quality sources available for maximum bioavailability.
Today NutraNomics has sales teams in seven different countries promoting its diversified line of wholefood-based supplements, specialty formulas, and remedies. All facilities used to produce the gluten-free, non-GMO nutritional products are cGMP Compliant and FDA approved. To ensure the highest purity potency and quality, the company takes it another step forward by performing additional content testing on all raw materials used to manufacture its products.
NutraNomics is more than just a health supplement provider. As a company dedicated to supporting the worldwide community of people who want to live healthy, NutraNomics is making an impact on those who are suffering from various types of diseases that need specialized diet to enhance their lifestyle. To fulfill this mission NutraNomics has invested in clinical studies for controlling diabetes, heart disease and cancer with dietary supplements. Strong growth is anticipated to continue as the company continues to introduce cutting-edge products and taps into new markets. Disclaimer
NutraNomics, Inc. Company Blog
NutraNomics, Inc. News:
Nutranomics Whole Food Based Vitamins and Supplements Joins Forces With Stonegate
RevNutrition.com to Carry Nutranomics Line of Non-Synthetic Supplements, Vitamins
Nutranomics Discusses Long-Term Global Expansion Strategy with UNO International Corp.
Ecrypt Technologies, Inc. (ECRY)
The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.1209, even for the day. The stock’s average daily volume over the past 60 days is 6,175 and its 52-week low/high is $0.055/$0.28.
Ecrypt Technologies, Inc. announced today that Dr. Thomas A. Cellucci, former Chief Commercialization Officer at the US Department of Homeland Security and the White House in both the Bush and Obama Administrations, who is regarded as an authority in rapid time-to-market new product development, was elected Chief Executive Officer by the Board of Directors after having joined the Board only earlier this year. His strengths include advanced strategic planning, market research, business intelligence and innovative public-private partnerships, and he comes to the Board of ECRY with the distinction of profitably growing multiple high-tech firms (at various levels) as his trademark.
Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.
Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.
The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.
Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer
Ecrypt Technologies, Inc. Blog
Ecrypt Technologies, Inc. News:
Ecrypt Technologies Appoints Dr. Thomas A. Cellucci as Chief Executive Officer
Ecrypt Technologies Appoints Former Microsoft Engineer to Advisory Board
Ecrypt Technologies Forms Advisory Board
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.0972, off by 2.90%, on 4,736,107 volume with 441 trades. The stock’s average daily volume over the past 60 days is 524,828, and its 52-week low/high is $0.10/$0.299.
International Stem Cell Corp. announced today the completion of the acute toxicity study of the Company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Completes Important Study in Parkinson's Disease Program
International Stem Cell Corporation to Present at BIO 2014
International Stem Cell Corporation Announces Positive R&D and Business Results for First Quarter 2014
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.29, up 20.83%, on 8,001 volume with 5 trades. The stock’s average daily volume over the past 60 days is 21,902, and its 52-week low/high is $0.21/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. Highlights Recent Media Coverage of MRSA
Zenosense, Inc. Provides Development Update
Zenosense, Inc. Extends License to Include Cancer Applications
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.125, even for the day, on 125,461 volume with 40 trades. The stock’s average daily volume over the past 60 days is 1,096,878, and its 52-week low/high is $0.005/$2.00.
Well Power Inc. (WPWR) has secured the US licensing rights to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and dilents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company is able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program
Flaring continues to be a problem - Well Power Inc. plans negotiations with MEC to acquire additional territories
Well Power Inc. corporate update
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) Receives Government Approval to Import 20,000 Metric Tons of Restricted Materials Annually
- Cal-Bay International, Inc. (CBYI) Receives $7M Capital Funding Proposal To Launch Marijuana Dispensary Card Payment Network
- Colt Resources Inc. (COLTF) CRME transaction and Richard Quesnel appointed Chair Advisory Board
- Consorteum Holdings, Inc. (CSRH) Signs Mobile Application Development Contract With Bet Butler Limited
- eCrypt Technologies, Inc. (ECRY) Appoints Dr. Thomas A. Cellucci as Chief Executive Officer
- Global Payout, Inc. (GOHE) European Subsidiary Launches Chip and PIN Prepaid MasterCard® Now Available Internationally
- Great Plains Holdings, Inc. (GTPH) Completes Final Phase of Real Estate Asset Project Ahead of Schedule
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Expands Management Team
- International Stem Cell Corp. (ISCO) Completes Important Study in Parkinson's Disease Program
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Issues Update on the Derbyshire Stone Quarry
- NeuroMama, Ltd. (NERO) CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented
- NutraNomics, Inc. (NNRX) Whole Food Based Vitamins and Supplements Joins Forces With Stonegate
- P2 Solar, Inc. (PTOS) Signs Implementation Agreement for Rajgarh Hydro Project
- Pan Global Corp. (PGLO) Shareholder Update: Anticipated Two Stage Completion of Small-Hydro Plant and Connection to Power Grid
- Raptor Resources Holdings Inc. (RRHI) Issues Update on the Derbyshire Stone Quarry
- Start Scientific, Inc. (STSC) is “One to Watch”
- Victory Energy Corp. (VYEY) Announces That the Noteholders of Target Energy Limited Have Voted to Approve Fairway Transaction
- VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
- Well Power Inc. (WPWR) Information to be Available through S&P Capital IQ Corporation Records Program
- WordLogic Corp. (WLGC) Announces Development of iOS 8 Version of Award-Winning iKnowU Keyboard
- Zenosense, Inc. (ZENO) Highlights Recent Media Coverage of MRSA